• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

DX-619及对照喹诺酮类药物对革兰氏阳性球菌的体外活性

In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.

作者信息

Wickman Paul A, Black Jennifer A, Moland Ellen Smith, Thomson Kenneth S

机构信息

Creighton University School of Medicine, Department of Medical Microbiology and Immunology, Center for Research in Anti-Infectives and Biotechnology, Omaha, NE 68178, USA.

出版信息

Antimicrob Agents Chemother. 2006 Jun;50(6):2255-7. doi: 10.1128/AAC.00011-06.

DOI:10.1128/AAC.00011-06
PMID:16723599
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1479102/
Abstract

The in vitro activity of the novel quinolone DX-619 was compared to those of currently available quinolones against U.S. clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus spp., Streptococcus pyogenes, and Streptococcus pneumoniae. DX-619 was the most potent quinolone overall, indicating possible utility as an anti-gram-positive quinolone.

摘要

将新型喹诺酮类药物DX - 619的体外活性与现有喹诺酮类药物针对美国临床分离的金黄色葡萄球菌、凝固酶阴性葡萄球菌、肠球菌属、化脓性链球菌和肺炎链球菌的活性进行了比较。总体而言，DX - 619是最有效的喹诺酮类药物，表明其作为抗革兰氏阳性喹诺酮类药物可能具有实用性。

相似文献

1
In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.DX-619及对照喹诺酮类药物对革兰氏阳性球菌的体外活性
Antimicrob Agents Chemother. 2006 Jun;50(6):2255-7. doi: 10.1128/AAC.00011-06.
2
Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.在印度南部一家三级眼科中心，比较从眼部感染中分离出的革兰阳性球菌对第二代和第四代喹诺酮类药物的体外药敏情况。
Eye (Lond). 2010 Jan;24(1):170-4. doi: 10.1038/eye.2009.29. Epub 2009 Feb 20.
3
Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.莫西沙星对环丙沙星敏感性降低的病原体的活性。
J Antimicrob Chemother. 1999 Nov;44(5):621-7. doi: 10.1093/jac/44.5.621.
4
[Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].[革兰氏阳性球菌临床分离株对氟喹诺酮类药物的耐药谱]
Biomedica. 2008 Jun;28(2):284-94.
5
In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.氟喹诺酮类药物对巴西圣保罗眼部细菌分离株的体外活性。
Cornea. 2007 Feb;26(2):194-8. doi: 10.1097/01.ico.0000248379.78777.f6.
6
In vitro activity of temafloxacin against gram-positive cocci including methicillin-resistant Staphylococcus aureus.替马沙星对包括耐甲氧西林金黄色葡萄球菌在内的革兰氏阳性球菌的体外活性。
Am J Med. 1991 Dec 30;91(6A):15S-18S. doi: 10.1016/0002-9343(91)90303-f.
7
Antistaphylococcal and antistreptococcal killing kinetics of ciprofloxacin, ofloxacin, sparfloxacin, and trovafloxacin.环丙沙星、氧氟沙星、司帕沙星和曲伐沙星对葡萄球菌和链球菌的杀菌动力学
Eur J Clin Microbiol Infect Dis. 1998 Nov;17(11):816-9. doi: 10.1007/s100960050199.
8
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.金黄色葡萄球菌和肺炎链球菌对不同氟喹诺酮类药物的耐药性选择及致突变性
Clin Microbiol Infect. 2005 Sep;11(9):750-8. doi: 10.1111/j.1469-0691.2005.01211.x.
9
Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.通过药敏试验和时间杀菌试验比较加替沙星与其他药物对金黄色葡萄球菌、化脓性链球菌及呼吸道病原体的活性。
J Antimicrob Chemother. 2003 Nov;52(5):869-72. doi: 10.1093/jac/dkg429. Epub 2003 Sep 30.
10
In vitro activity of DX-619, a novel des-fluoro(6) quinolone, against a panel of Streptococcus pneumoniae mutants with characterized resistance mechanisms.新型去氟（6）喹诺酮类药物DX-619对一组具有明确耐药机制的肺炎链球菌突变株的体外活性。
Antimicrob Agents Chemother. 2006 Feb;50(2):796-8. doi: 10.1128/AAC.50.2.796-798.2006.

引用本文的文献

1
Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America.临床实践指南：A 组链球菌咽炎的诊断和管理：美国传染病学会 2012 年更新版。
Clin Infect Dis. 2012 Nov 15;55(10):e86-102. doi: 10.1093/cid/cis629. Epub 2012 Sep 9.
2
Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.多重耐药肺炎链球菌感染：当前及未来的治疗选择
Drugs. 2007;67(16):2355-82. doi: 10.2165/00003495-200767160-00005.
3
Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol.新型去氟（6）-喹诺酮DX-619对通过冷碘海醇血清清除率测定的肾小球滤过率无影响。
Antimicrob Agents Chemother. 2007 Jun;51(6):1912-7. doi: 10.1128/AAC.01223-06. Epub 2007 Mar 19.

本文引用的文献

1
Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.新型去F(6)-喹诺酮类药物DX-619与其他药物相比的抗葡萄球菌活性。
Antimicrob Agents Chemother. 2005 Aug;49(8):3325-33. doi: 10.1128/AAC.49.8.3325-3333.2005.
2
In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.新型去氟（6）喹诺酮DX-619的体外抗菌活性
Antimicrob Agents Chemother. 2005 Jul;49(7):3040-5. doi: 10.1128/AAC.49.7.3040-3045.2005.
3
The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.具有喹诺酮耐药性突变的肺炎链球菌的分子流行病学
Clin Infect Dis. 2005 Jan 15;40(2):225-35. doi: 10.1086/426817. Epub 2004 Dec 21.
4
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.国家医院感染监测（NNIS）系统报告，1992年1月至2003年6月数据总结，2003年8月发布。
Am J Infect Control. 2003 Dec;31(8):481-98. doi: 10.1016/j.ajic.2003.09.002.
5
Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones.与其他五种氟喹诺酮类药物相比，耐莫西沙星金黄色葡萄球菌的选择
J Antimicrob Chemother. 2003 Jun;51(6):1403-7. doi: 10.1093/jac/dkg241. Epub 2003 Apr 25.
6
Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model.成人社区获得性肺炎门诊治疗中抗菌药物耐药性对健康结局的影响：概率模型
J Antimicrob Chemother. 2003 May;51(5):1269-82. doi: 10.1093/jac/dkg220. Epub 2003 Apr 14.
7
Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.自1994 - 1995年以来美国肺炎链球菌对氟喹诺酮类药物的耐药性
Antimicrob Agents Chemother. 2002 Mar;46(3):680-8. doi: 10.1128/AAC.46.3.680-688.2002.
8
National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001.国家医院感染监测（NNIS）系统报告，1992年1月至2001年6月数据总结，2001年8月发布。
Am J Infect Control. 2001 Dec;29(6):404-21. doi: 10.1067/mic.2001.119952.
9
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.1999 - 2000年美国肺炎链球菌临床分离株的抗菌药物耐药性，包括1994 - 1995年以来耐药率的比较。
Antimicrob Agents Chemother. 2001 Jun;45(6):1721-9. doi: 10.1128/AAC.45.6.1721-1729.2001.
10
Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.葡萄球菌属感染调查：1997 - 1999年美国、加拿大、拉丁美洲、欧洲及西太平洋地区为哨兵抗菌监测计划收集的分离株的发生频率及抗菌药敏情况
Clin Infect Dis. 2001 May 15;32 Suppl 2:S114-32. doi: 10.1086/320184.